Connection

KEVIN GAREY to Tetracyclines

This is a "connection" page, showing publications KEVIN GAREY has written about Tetracyclines.
Connection Strength

1.525
  1. Phase I trial comparing bile acid and short-chain fatty acid alterations in stool collected from human subjects treated with omadacycline or vancomycin. Antimicrob Agents Chemother. 2025 Feb 13; 69(2):e0125124.
    View in: PubMed
    Score: 0.977
  2. Development and validation of LC-MS/MS for quantifying omadacycline from stool for gut microbiome studies. J Chromatogr B Analyt Technol Biomed Life Sci. 2024 Apr 01; 1236:124057.
    View in: PubMed
    Score: 0.230
  3. Fecal Pharmacokinetics and Gut Microbiome Effects of Oral Omadacycline Versus Vancomycin in Healthy Volunteers. J Infect Dis. 2024 01 12; 229(1):273-281.
    View in: PubMed
    Score: 0.228
  4. In vitro activity of eravacycline against common ribotypes of Clostridioides difficile. J Antimicrob Chemother. 2020 10 01; 75(10):2879-2884.
    View in: PubMed
    Score: 0.045
  5. In Vitro Activity of Omadacycline, a New Tetracycline Analog, and Comparators against Clostridioides difficile. Antimicrob Agents Chemother. 2020 07 22; 64(8).
    View in: PubMed
    Score: 0.045
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.